CN101360486B - 用于蛋白质药物递送的毫微粒 - Google Patents

用于蛋白质药物递送的毫微粒 Download PDF

Info

Publication number
CN101360486B
CN101360486B CN2005800449397A CN200580044939A CN101360486B CN 101360486 B CN101360486 B CN 101360486B CN 2005800449397 A CN2005800449397 A CN 2005800449397A CN 200580044939 A CN200580044939 A CN 200580044939A CN 101360486 B CN101360486 B CN 101360486B
Authority
CN
China
Prior art keywords
nanoparticle
preparation according
nanoparticles
insulin
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800449397A
Other languages
English (en)
Chinese (zh)
Other versions
CN101360486A (zh
Inventor
涂鸿生
宋信文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NANOMEGA MEDICAL CORP
Original Assignee
NANOMEGA MEDICAL CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/029,082 external-priority patent/US7265090B2/en
Application filed by NANOMEGA MEDICAL CORP filed Critical NANOMEGA MEDICAL CORP
Publication of CN101360486A publication Critical patent/CN101360486A/zh
Application granted granted Critical
Publication of CN101360486B publication Critical patent/CN101360486B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2005800449397A 2005-01-04 2005-12-27 用于蛋白质药物递送的毫微粒 Expired - Fee Related CN101360486B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/029,082 2005-01-04
US11/029,082 US7265090B2 (en) 2004-10-05 2005-01-04 Nanoparticles for paracellular drug delivery
US11/284,734 2005-11-21
US11/284,734 US7282194B2 (en) 2004-10-05 2005-11-21 Nanoparticles for protein drug delivery
PCT/US2005/047125 WO2006073950A2 (en) 2005-01-04 2005-12-27 Nanoparticles for protein drug delivery

Publications (2)

Publication Number Publication Date
CN101360486A CN101360486A (zh) 2009-02-04
CN101360486B true CN101360486B (zh) 2012-09-05

Family

ID=36648027

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800449397A Expired - Fee Related CN101360486B (zh) 2005-01-04 2005-12-27 用于蛋白质药物递送的毫微粒

Country Status (8)

Country Link
US (4) US7282194B2 (cg-RX-API-DMAC10.html)
EP (1) EP1833470A4 (cg-RX-API-DMAC10.html)
JP (2) JP5384831B2 (cg-RX-API-DMAC10.html)
CN (1) CN101360486B (cg-RX-API-DMAC10.html)
AU (1) AU2005322940B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0518093A (cg-RX-API-DMAC10.html)
CA (1) CA2592991C (cg-RX-API-DMAC10.html)
WO (1) WO2006073950A2 (cg-RX-API-DMAC10.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137697B1 (en) * 2004-10-05 2012-03-20 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US7901711B1 (en) * 2006-04-17 2011-03-08 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541028B2 (en) * 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
EP1774971A1 (en) * 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Chitosan and heparin nanoparticles
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
ATE504236T1 (de) * 2006-02-27 2011-04-15 Edwards Lifesciences Corp Wassergel für intravenösen amperometrischen biosensor
JP2007291324A (ja) * 2006-03-31 2007-11-08 Jsr Corp 酸化物微粒子含有ポリシロキサン組成物およびその製造方法
JP2007270056A (ja) * 2006-03-31 2007-10-18 Jsr Corp 金属酸化物微粒子含有ポリシロキサン組成物およびその製造方法
US8449915B1 (en) * 2006-04-17 2013-05-28 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20080160096A1 (en) * 2006-07-27 2008-07-03 Janos Berbely Polymeric nanoparticles by ion-ion interactions
CN101148511B (zh) * 2006-09-18 2010-10-20 中国科学院过程工程研究所 荧光壳聚糖微球的制备方法及其在示踪剂领域的应用
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
JP5285617B2 (ja) * 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション 生きたプロバイオティクスを含む乾燥食物製品
US20080193547A1 (en) * 2006-12-27 2008-08-14 Janos Borbely Polymeric nanoparticles by ion-ion Interactions
DK2155255T3 (da) * 2007-05-09 2013-09-02 Nitto Denko Corp Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat
WO2009035438A1 (en) * 2007-09-13 2009-03-19 Janos Borbely Polymeric nanoparticles by ion-ion interactions
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
EP2296637B1 (en) * 2008-04-24 2014-04-02 Medtronic, Inc Chitosan-containing protective composition
CA2721937C (en) 2008-04-24 2016-07-12 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
JP5711113B2 (ja) * 2008-04-24 2015-04-30 メドトロニック，インコーポレイテッド チオール化キトサンゲル
CA2722145A1 (en) * 2008-04-24 2009-10-29 Medtronic, Inc. Rehydratable thiolated polysaccharide particles and sponge
US8653319B2 (en) 2008-04-24 2014-02-18 Medtronic, Inc. Cold ionizing radiation sterilization
WO2010001932A1 (ja) * 2008-07-01 2010-01-07 日東電工株式会社 表面被覆微粒子の医薬組成物
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8241654B2 (en) * 2008-09-26 2012-08-14 Tyco Healthcare Group Lp Reactive surgical implant
US20100104608A1 (en) * 2008-09-26 2010-04-29 Tyco Healthcare Group Lp Reactive surgical implant
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US20100111919A1 (en) * 2008-10-31 2010-05-06 Tyco Healthcare Group Lp Delayed gelation compositions and methods of use
JP2010132609A (ja) * 2008-12-05 2010-06-17 Fujifilm Corp カゼインナノ粒子
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
WO2010087781A1 (en) * 2009-01-28 2010-08-05 Agency For Science, Technology And Research Polyelectrolyte complexes with bound peptides
EP3266448B1 (en) 2009-03-27 2022-02-16 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
SG176253A1 (en) 2009-05-26 2011-12-29 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US8404281B2 (en) 2009-06-08 2013-03-26 Avant Garde Therapeutics & Technologies Llc Formulations
EP2446899B1 (en) * 2009-06-25 2020-09-30 Bioleaders Corporation Adjuvant composition comprising (poly-gamma-glutamate)-chitosan nanoparticles
IN2012DN00311A (cg-RX-API-DMAC10.html) 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd
US8637096B2 (en) 2009-12-04 2014-01-28 Curtis C. Stojan Compositions and method for enhancing insulin activity
NZ601017A (en) 2010-01-28 2014-07-25 Advanced Bionutrition Corp Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
EP2547328B1 (en) * 2010-02-11 2017-06-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) Ccr7 ligand delivery and co-delivery in immunotherapy
JP2011178764A (ja) * 2010-03-04 2011-09-15 Ajinomoto Co Inc 腸内ビフィズス菌増殖促進剤および腸管バリア機能改善剤
EP2417968A1 (en) 2010-07-29 2012-02-15 Consorzio per il Centro di Biomedicina Molecolare Scrl Particle comprising cytokines, antibodies and polymers and use thereof as medicament for the treatment of cancer
CL2011001984A1 (es) 2010-08-13 2012-06-29 Advanced Bionutrition Corp Composicion seca estabilizadora para material biologico que comprende carbohidrato, proteinas hidrolizadas de animal o de planta y un componente de acido carboxilico; metodo de preparacion; y formulacion de entrega oral que comprende la composicion seca estabilizadora.
EP2645991B1 (en) 2010-12-02 2020-02-12 GreenMark Biomedical Inc. Aptamer bioconjugate drug delivery device
US9713702B2 (en) * 2011-03-14 2017-07-25 The Board Of Trustee Of The Leland Stanford Junior University Methods of electric field induced delivery of compounds, compositions used in delivery, and systems of delivery
WO2012170017A1 (en) * 2011-06-08 2012-12-13 Avant Garde Therapeutics Inc. Novel formulations
CA2869821C (en) 2011-06-13 2018-06-19 Rival, Societe En Commandite N,n,n-trialkylaminopolymers, methods of their preparation and uses thereof
JP5801626B2 (ja) * 2011-06-30 2015-10-28 国立大学法人信州大学 複合ナノ繊維の製造方法
AU2012318273B2 (en) * 2011-12-02 2016-05-19 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
US8883717B2 (en) * 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
TWI511744B (zh) * 2013-01-09 2015-12-11 Univ Nat Cheng Kung 可任意調整介面電荷與粒徑大小之生物可分解載體、其製備方法及含彼之醫藥組合物
US11504422B2 (en) 2013-01-09 2022-11-22 National Cheng Kung University Biodegradable nanocomplex
WO2015032971A1 (en) * 2013-09-09 2015-03-12 Lek Pharmaceuticals D.D. Polymer selection for preparation of nps with high protein loading
WO2015049689A1 (en) 2013-10-01 2015-04-09 Ray Manju Sustained release formulations containing methylglyoxal and their therapeutic applications
EP3065782B8 (en) * 2013-11-05 2021-05-26 Elena Molokanova Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels
CN103656623B (zh) * 2013-12-06 2015-04-15 南通大学 载有神经营养因子的纳米微球及制备和用途
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2015176031A2 (en) 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US20170304374A1 (en) * 2014-10-23 2017-10-26 Symbiotic Health Inc. Capsule for the oral administration of biopharmaceuticals
AU2016257813B2 (en) 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
EP3328215B1 (en) 2015-07-29 2021-07-07 Advanced BioNutrition Corp. Stable dry probiotic compositions for special dietary uses
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
KR101882820B1 (ko) 2015-12-30 2018-07-30 주식회사 삼양바이오팜 점막부착성 약학 조성물 및 그의 제조방법
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
CN108778257B (zh) * 2017-01-19 2021-11-16 中山大学 负载治疗性蛋白质的纳米粒及其制备方法
CN107651664B (zh) * 2017-10-16 2020-11-06 浙江领蔚生物技术有限公司 一种荧光碳纳米粒子及用作细胞标记材料的用途
CN111918675A (zh) 2018-03-28 2020-11-10 格林马克生物医药股份有限公司 磷酸盐交联淀粉纳米颗粒和牙科治疗
EP4369942A1 (en) 2021-07-12 2024-05-22 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers
CN114470186B (zh) * 2022-02-17 2023-10-20 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
KR20250144708A (ko) * 2024-03-27 2025-10-13 한국과학기술연구원 올리고감마글루탐산 유도체 기반의 신규한 지질 및 이를 포함하는 지질나노입자와 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1379687A (zh) * 1999-09-14 2002-11-13 生物医学阿佩则系统有限公司 具有生化活性的磁性毫微粒、其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507070A (ja) * 1993-02-22 1996-07-30 アルザ・コーポレーション 活性物質の経口投与のための組成物
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
DE69712110T2 (de) * 1996-07-10 2002-12-12 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Ltd., Nottingham Zusammensetzungen zur einführung von genen in epithelzellen
US6933331B2 (en) * 1998-05-22 2005-08-23 Nanoproducts Corporation Nanotechnology for drug delivery, contrast agents and biomedical implants
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
IE970794A1 (en) * 1997-09-24 2000-08-23 Elan Corp Plc Composition and method for enhancing paracellular transport across cell layers
US6726934B1 (en) * 1997-10-09 2004-04-27 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
WO1999018934A1 (en) * 1997-10-09 1999-04-22 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
US6517869B1 (en) * 1997-12-12 2003-02-11 Expression Genetics, Inc. Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
FR2780901B1 (fr) * 1998-07-09 2000-09-29 Coletica Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
WO2000064954A1 (en) * 1999-04-22 2000-11-02 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
CA2372461A1 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates
WO2001001964A2 (en) * 1999-06-23 2001-01-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7482018B2 (en) * 2001-12-21 2009-01-27 Soane Family Trust Use of oligomers and polymers for drug solubilization, stabilization, and delivery
GB0302738D0 (en) 2003-02-06 2003-03-12 Advanced Biopolymers As Composition
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.
US7265090B2 (en) * 2004-10-05 2007-09-04 Gp Medical, Inc. Nanoparticles for paracellular drug delivery
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541046B1 (en) * 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7879819B1 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7611690B2 (en) * 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7291598B2 (en) 2005-01-04 2007-11-06 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541028B2 (en) * 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
US7604795B1 (en) * 2005-01-04 2009-10-20 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1379687A (zh) * 1999-09-14 2002-11-13 生物医学阿佩则系统有限公司 具有生化活性的磁性毫微粒、其制备方法和应用

Also Published As

Publication number Publication date
EP1833470A4 (en) 2012-08-22
US7282194B2 (en) 2007-10-16
WO2006073950A3 (en) 2008-10-30
AU2005322940A1 (en) 2006-07-13
JP5384831B2 (ja) 2014-01-08
US7455830B2 (en) 2008-11-25
CN101360486A (zh) 2009-02-04
US8454966B2 (en) 2013-06-04
EP1833470A2 (en) 2007-09-19
US20100330167A1 (en) 2010-12-30
US7803748B2 (en) 2010-09-28
US20080213354A1 (en) 2008-09-04
JP2013177434A (ja) 2013-09-09
AU2005322940B2 (en) 2010-07-08
JP2008528446A (ja) 2008-07-31
CA2592991A1 (en) 2006-07-13
HK1122508A1 (en) 2009-05-22
WO2006073950A2 (en) 2006-07-13
BRPI0518093A (pt) 2008-10-28
WO2006073950B1 (en) 2008-12-11
CA2592991C (en) 2012-09-11
US20080233200A1 (en) 2008-09-25
US20060147539A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
CN101360486A (zh) 用于蛋白质药物递送的毫微粒
US7556826B2 (en) Nanoparticles for protein drug delivery
US7541046B1 (en) Nanoparticles for protein drug delivery
US7291598B2 (en) Nanoparticles for protein drug delivery
US7611690B2 (en) Nanoparticles for protein drug delivery
US7604795B1 (en) Nanoparticles for protein drug delivery
US20070243259A1 (en) Nanoparticles for protein/peptide delivery and delivery means
CN102970864A (zh) 纳米颗粒药物组合物
US7265090B2 (en) Nanoparticles for paracellular drug delivery
US7541028B2 (en) Nanoparticles for monoclonal antibody delivery
US7381716B2 (en) Nanoparticles for protein drug delivery
US7871988B1 (en) Nanoparticles for protein drug delivery
US8461316B1 (en) Nanoparticles for delivery of bioactive agents
US7863258B1 (en) Nanoparticles for protein drug delivery
HK1122508B (en) Nanoparticles for protein drug delivery
US7879312B1 (en) Nanoparticles for protein drug delivery
US7871989B1 (en) Nanoparticles for protein drug delivery
Vaidya et al. Biodegradable Polymers: Protein Therapeutics Delivery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1122508

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1122508

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120905

Termination date: 20161227